Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

521.20INR
15 Dec 2017
Change (% chg)

Rs7.65 (+1.49%)
Prev Close
Rs513.55
Open
Rs517.00
Day's High
Rs523.40
Day's Low
Rs515.70
Volume
1,032,766
Avg. Vol
3,028,128
52-wk High
Rs530.80
52-wk Low
Rs293.90

Select another date:

Wed, Dec 13 2017

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

BRIEF-Biocon ‍launches Krabeva in India​

* Launches Krabeva - biosimilar Bevacizumab for treating several types of cancer in India​

BRIEF-Biocon says co's facility receives EIR with VAI status​

* Says ‍Biocon's facility receives EIR with vai status​ Source text for Eikon: Further company coverage:

India's Biocon Q2 profit more than halves

Oct 26 India's Biocon Ltd posted a 53 percent fall in quarterly profit on Thursday, missing estimates, as higher costs at its Malaysia plant and pricing pressures in its active pharmaceutical ingredients business weighed.

BRIEF-India's Biocon Sept-qtr consol profit more than halves

* Sept quarter consol profit 688 million rupees versus 1.47 billion rupees last year

BRIEF-Biocon says US FDA completes inspection with no observations for Vishakhapatnam facility

* Says Biocon's facility in Vishakhapatnam completes USFDA inspection with no observations Source text for Eikon: Further company coverage:

BRIEF-Biocon says insulins facility in Malaysia gets EU GMP compliance certificate

* Says Biocon's insulins facility in Malaysia receives EU GMP compliance certificate Source text - http://bit.ly/2waGftz Further company coverage:

BRIEF-Biocon announces partnership with JDRF to support study of oral insulin drug candidate

* Says JDRF supports biocon study of novel, fast-acting oral insulin tregopil for type 1 diabetes treatment Source text - http://bit.ly/2wEFaOf Further company coverage:

Select another date: